SC411

A New Paradigm in Sickle Cell Disease Treatment for Children through a Proprietary Platform for Enhanced Absorption of Lipophilic Drugs. SC411 is an investigational drug that uses ALT designed to prevent painful crises in Sickle Cell Disease patients. SC411 Product Benefits The largest study ever conducted in support that Omega-3 is safe and well tolerated […]

Read More
SC403

A phase-2 treatment for Short Bowel Syndrome (SBS) through a Proprietary Platform for Enhanced Absorption of Lipophilic Drugs. SC403 with the Advanced Lipid Technologies™(ALT®) Platform is an investigational drug designed to treat Pediatric Short Bowel Syndrome through increased bioavailability, which may promote intestinal adaptation and reduce the requirements of parenteral nutrition. Major Milestones Preclinical studies […]

Read More